{"id":5274,"date":"2019-06-18T14:38:59","date_gmt":"2019-06-18T09:08:59","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5274"},"modified":"2021-07-24T12:57:24","modified_gmt":"2021-07-24T07:27:24","slug":"notizia-zynteglo","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-zynteglo","title":{"rendered":"Notizia"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><strong>Bluebird&nbsp;declares the price of its gene therapy- Zynteglo\n<\/strong><\/h4>\n\n\n\n<p><strong>Bluebird Bio<\/strong> has set the price of its gene therapy <strong>Zynteglo<\/strong> at <strong>USD 1.8 million<\/strong>. Zynteglo, so far, has only been approved for treating rare blood disorders in the Europe Union. The full price of Zynteglo can be dispersed out for five years, at approximately USD 357,567 annually. The first gene therapy was the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-muscular-atrophy-market-insights-epidemiology-and-market-forecast\">spinal muscular atrophy<\/a><\/strong> treatment <strong>Zolgensma<\/strong>, which was approved by the FDA last month. Its developer, Novartis, kept the price of the therapy at USD 2.1 million. These one-time therapies can have a life-long effect in treating diseases as compared to traditional medicines. But the huge upfront cost, to be borne by the patient, dispirits patients to opt for it. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Pfizer is set to acquire Array BioPharma<\/strong><\/h4>\n\n\n\n<p><strong>Pfizer <\/strong>has declared to buy oncology specialist Array BioPharma for a total value of about <strong>USD 11.4 billion<\/strong>. The two companies have entered into a definitive merger agreement according to which Pfizer will procure <strong>Array<\/strong>&#8211; a commercial stage biopharmaceutical company focused on the discovery, development and commercialisation of targeted small molecule medicines to treat <a href=\"https:\/\/www.delveinsight.com\/report-store\/medullary-thyroid-cancer-market\">cancer <\/a>and other diseases of high unmet need. The proposed acquisition will let Pfizer attain the rights over two marketed drugs, MEK inhibitor Mektovi and BRAF inhibitor Braftovi, accelerating its oncology treatment. \u00a0The two drugs, <strong>Mektovi <\/strong>and <strong>Braftovi <\/strong>are approved as a combo treatment for melanoma and recently showed positive results in treating colon cancer. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Jazz Pharmaceuticals plans an early launch of its drug Sunosi<\/strong><\/h4>\n\n\n\n<p><strong>Jazz Pharmaceuticals<\/strong> is planning to launch its sleepiness medicine Sunosi, which is also known as solriamfetol sooner than planned after it received a Schedule IV medicine designation from the U.S. Drug Enforcement Agency (DEA). Sunosi received an FDA approval in March this year, is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI). The drug promises to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). At present, the<strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/obstructive-sleep-apnea-osa-market-insights-epidemiology-and-market-forecast\">Obstructive sleep apnea treatment market <\/a><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/obstructive-sleep-apnea-osa-market-insights-epidemiology-and-market-forecast\">i<\/a>ncludes <strong>Provigil Oral<\/strong> and <strong>Nuvigil Oral<\/strong> as the only approved marketed drugs in the US. Looking at the overall market scenario, DelveInsight\u2019s estimated that the Obstructive Sleep Apnea Market size was about<strong> USD 197.46 Million<\/strong> in 2016 in 7MM for the period of 2016-2027. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bluebird&nbsp;declares the price of its gene therapy- Zynteglo Bluebird Bio has set the price of its gene therapy Zynteglo at USD 1.8 million. Zynteglo, so far, has only been approved for treating rare blood disorders in the Europe Union. The full price of Zynteglo can be dispersed out for five years, at approximately USD 357,567 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5080,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1840,730,423,460,4221,4575],"industry":[17225],"therapeutic_areas":[17235,17506],"class_list":["post-5274","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-drug-discovery","tag-notizia","tag-novartis","tag-pfizer","tag-zolgensma","tag-zynteglo","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-sleep-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia 18\/06\/2019 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Bluebird Bio has set the price of its gene therapy Zynteglo at USD 1.8 million. Zynteglo, so far, has only been approved for treating rare blood disorder...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-zynteglo\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 18\/06\/2019 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Bluebird Bio has set the price of its gene therapy Zynteglo at USD 1.8 million. Zynteglo, so far, has only been approved for treating rare blood disorder...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-zynteglo\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-06-18T09:08:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 18\/06\/2019 - DelveInsight Business Research","description":"Bluebird Bio has set the price of its gene therapy Zynteglo at USD 1.8 million. Zynteglo, so far, has only been approved for treating rare blood disorder...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-zynteglo","og_locale":"en_US","og_type":"article","og_title":"Notizia 18\/06\/2019 - DelveInsight Business Research","og_description":"Bluebird Bio has set the price of its gene therapy Zynteglo at USD 1.8 million. Zynteglo, so far, has only been approved for treating rare blood disorder...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-zynteglo","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-06-18T09:08:59+00:00","article_modified_time":"2021-07-24T07:27:24+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-zynteglo","url":"https:\/\/www.delveinsight.com\/blog\/notizia-zynteglo","name":"Notizia 18\/06\/2019 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-zynteglo#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-zynteglo#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","datePublished":"2019-06-18T09:08:59+00:00","dateModified":"2021-07-24T07:27:24+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Bluebird Bio has set the price of its gene therapy Zynteglo at USD 1.8 million. Zynteglo, so far, has only been approved for treating rare blood disorder...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-zynteglo"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-zynteglo#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","width":647,"height":345,"caption":"Recent Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">drug discovery<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Zolgensma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Zynteglo<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">drug discovery<\/span>","<span class=\"advgb-post-tax-term\">Notizia<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Zolgensma<\/span>","<span class=\"advgb-post-tax-term\">Zynteglo<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jun 18, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jun 18, 2019 2:38 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Recent Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5274"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5274\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5080"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5274"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5274"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}